Significant segment expenses (Tables)

12 Months Ended

Dec. 31, 2024

Significant segment expenses

Schedule of significant segment expenses

	Year Ended December 31,
	2024		2023
Operating expenses
Research and development
Clinical trial	$	14,441	$	5,100
Costs under the Shared Services Agreement with Dong-A (related party)		4,930		2,438
Employee compensation and benefits		1,606		461
Consulting		288		483
Other (1)		288		676
Total research and development		21,553		9,158
General and administrative
Legal and professional fees		2,864		3,007
Consulting		1,533		1,961
Employee compensation and benefits		1,659		620
Other (2)		1,200		1,140
Total general and administrative		7,256		6,728
Total operating expenses	$	28,809	$	15,886

(1) Other R&D expenses include non-clinical and preclinical services and other R&D expenditures.

(2) Other G&A expenses include insurance, software license fees, non-income state taxes, lease rental expenses and other G&A expenditures.